Amylin Reports Positive Results For Obesity Study

Amylin has announced positive results from a 28-week dose-ranging study of pramlintide/metreleptin, a combination treatment comprising pramlintide and metreleptin in overweight and obese patients. This phase-II study successfully characterized patients who responded best to treatment, and also provided important information to inform dose selection.

The phase-II, 28-week, double-blind, placebo-controlled multi-center study randomized 608 obese/overweight patients.

In the overall evaluable study population, all of the pramlintide/metreleptin combination arms achieved more weight loss than placebo. The study results confirmed previous phase-II results with the combination therapy, and provide a foundation for the company’s ongoing obesity development program.

Christian Weyer, Vice President of corporate development, diabetes and obesity at Amylin, said: These findings provide us with valuable data that will inform our clinical and product development strategy moving forward.

Our integrated neurohormonal approach to obesity provides a broad research and development platform that has the potential to yield transformational therapies that address a range of unmet patient needs across the various classes of obesity, he added.